Investigation Overview
An investigation on behalf of current investors of Genzyme Corporation (NASDAQ:GENZ) over potential breaches of fiduciary duty by the Genzyme board of directors in the event of agreeing to an unfair takeover was announced. Rumors about a potential buyout of biotechnology company Genzyme have hit the market on July 23, 2010 causing Genzyme shares (GENZ) to jump from $54 to $65 on July...
You must register (for free) or login to view the entire investigation.